BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu Y, Liu Y, Lu J, Cao Z, Jin Y, Ma L, Geng N, Ren S, Zheng Y, Shen C, Chen X. Durability of Interferon-induced Hepatitis B Surface Antigen Seroclearance. Clinical Gastroenterology and Hepatology 2020;18:514-516.e2. [DOI: 10.1016/j.cgh.2019.04.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Mo Z, Gan W, Zhao Q, Yin Y, Gao Z. Functional cure of chronic hepatitis B: Efforts and prospects. Liver Research 2020;4:1-4. [DOI: 10.1016/j.livres.2020.02.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Mao QG, Liang HQ, Yin YL, Tang JM, Yang JE, Wu CC, Chen Y, Zhang MY, Liu YY, Zheng XT, Zhuang LY, Chen SD. Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B. Clin Res Hepatol Gastroenterol 2021;:101758. [PMID: 34303003 DOI: 10.1016/j.clinre.2021.101758] [Reference Citation Analysis]
3 Li R, Lin X, Wang JY, Wang X, Lu J, Liu Y, Cao Z, Ren S, Ma L, Jin Y, Zheng S, Hu Z, Wang L, Chen X. Cost-effectiveness of combination antiviral treatment with extended duration for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China. Ann Transl Med 2021;9:1365. [PMID: 34733917 DOI: 10.21037/atm-21-1666] [Reference Citation Analysis]
4 Song A, Wang X, Lu J, Jin Y, Ma L, Hu Z, Zheng Y, Shen C, Chen X. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta-analysis. J Viral Hepat 2021;28:601-12. [PMID: 33455067 DOI: 10.1111/jvh.13471] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Yip TC, Lok AS. How Do We Determine Whether a Functional Cure for HBV Infection Has Been Achieved? Clin Gastroenterol Hepatol. 2020;18:548-550. [PMID: 31446185 DOI: 10.1016/j.cgh.2019.08.033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
6 Zeng QL, Yu ZJ, Shang J, Xu GH, Sun CY, Liu N, Li CX, Lv J, Liu YM, Liang HX, Li ZQ, Pan YJ, Hu QY, Li W, Zhang DW, Wang FS. Short-term Peginterferon-Induced High Functional Cure Rate in Inactive Chronic Hepatitis B Virus Carriers With Low Surface Antigen Levels. Open Forum Infect Dis 2020;7:ofaa208. [PMID: 32626791 DOI: 10.1093/ofid/ofaa208] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Wu F, Lu R, Liu Y, Wang Y, Tian Y, Li Y, Li M, Wang W, Zhang X, Jia X, Dang S. Efficacy and safety of peginterferon alpha monotherapy in Chinese inactive chronic hepatitis B virus carriers. Liver Int 2021;41:2032-45. [PMID: 33896094 DOI: 10.1111/liv.14897] [Reference Citation Analysis]
8 Li M, Sun F, Bi X, Lin Y, Yang L, Lu Y, Zhang L, Wan G, Yi W, Zhao L, Xie Y. Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients. Virologica Sinica 2022. [DOI: 10.1016/j.virs.2022.03.001] [Reference Citation Analysis]
9 Xu X, Nie R, Huang J, Yang L. Chemiluminescent Optical Fiber Immunosensor Combining Surface Modification and Signal Amplification for Ultrasensitive Determination of Hepatitis B Antigen. Sensors (Basel) 2020;20:E4912. [PMID: 32878030 DOI: 10.3390/s20174912] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Nishio A, Bolte FJ, Takeda K, Park N, Yu ZX, Park H, Valdez K, Ghany MG, Rehermann B. Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection. Sci Transl Med 2021;13:eaba6322. [PMID: 33790025 DOI: 10.1126/scitranslmed.aba6322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Kaur SP, Talat A, Karimi-Sari H, Grees A, Chen HW, Lau DTY, Catana AM. Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg). J Clin Med 2022;11:1126. [PMID: 35207397 DOI: 10.3390/jcm11041126] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Nayagam JS, Cargill ZC, Agarwal K. The Role of RNA Interference in Functional Cure Strategies for Chronic Hepatitis B. Curr Hepatology Rep 2020;19:362-9. [DOI: 10.1007/s11901-020-00548-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Song A, Lin X, Chen X. Functional cure for chronic hepatitis B: accessibility, durability, and prognosis. Virol J 2021;18:114. [PMID: 34082765 DOI: 10.1186/s12985-021-01589-x] [Reference Citation Analysis]
14 Lok AS, Zoulim F, Dusheiko G, Chan HLY, Buti M, Ghany MG, Gaggar A, Yang JC, Wu G, Flaherty JF, Subramanian GM, Locarnini S, Marcellin P. Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B. Hepatol Commun 2020;4:8-20. [PMID: 31909352 DOI: 10.1002/hep4.1436] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
15 Cheng K, Chen Y, Wang X, Xu M, Liao W, Duan X, Zhao X, Sun Y, Duan Z, Wang L. Entecavir combined with interferon-α is superior to entecavir monotherapy in reducing hepatic and extrahepatic cancer in patients with chronic hepatitis B. Cancer 2021. [PMID: 34623636 DOI: 10.1002/cncr.33949] [Reference Citation Analysis]